Foretinib (GSK1363089): ATP-Competitive Multikinase Inhibitor for Cancer Research

Executive Summary: Foretinib (GSK1363089) is a potent ATP-competitive multikinase inhibitor targeting VEGFR, HGFR/Met, and several additional tyrosine kinases with nanomolar IC₅₀ values (0.4–9.6 nmol/L), which enables effective suppression of tumor cell proliferation and metastasis (APExBIO). In vitro, Foretinib demonstrates robust inhibition of MET signaling (IC₅₀ ≈ 21–23 nmol/L) across diverse cell lines and induces G2/M cell cycle arrest (Schwartz 2022). Its efficacy is further confirmed in vivo, where oral administration (30 mg/kg) significantly reduces tumor burden in xenograft models. Foretinib is insoluble in water but highly soluble in DMSO (≥31.65 mg/mL), making careful stock preparation essential for reproducibility. This dossier synthesizes peer-reviewed and product-verified data to inform advanced oncology workflows.

Biological Rationale

Receptor tyrosine kinases (RTKs) such as VEGFR and HGFR/Met are key regulators of tumor angiogenesis, proliferation, and metastatic capacity. Aberrant activation of these pathways contributes to cancer progression and therapeutic resistance (Schwartz 2022). Targeting multiple RTKs simultaneously with a single molecule such as Foretinib can disrupt redundant oncogenic signaling networks. This strategy aims to overcome compensatory mechanisms that limit the efficacy of single-target therapies. Foretinib’s multikinase profile includes inhibition of VEGFR2 (KDR), VEGFR3 (Flt-4), c-Met, Ron, KIT, Flt-3, PDGFRα/β, and Tie-2, making it suitable for dissecting complex tumor biology and microenvironmental interactions. The rationale for using Foretinib lies in its ability to block both tumor cell-intrinsic and microenvironment-dependent signaling, thus impairing growth, motility, and metastasis.

Mechanism of Action of Foretinib (GSK1363089)

Foretinib is a small-molecule, ATP-competitive inhibitor that binds to the catalytic domain of targeted RTKs. It inhibits receptor phosphorylation and downstream signaling by occupying the ATP binding site. Quantitative kinase assays confirm that Foretinib’s IC₅₀ values for VEGFR2, VEGFR3, Met, and Ron are in the nanomolar range (0.4–9.6 nmol/L) (APExBIO). Cellular assays in B16F10 (murine melanoma), PC-3 (prostate), A549 (lung), and HT29 (colon) cancer lines reveal that Foretinib inhibits MET phosphorylation with an IC₅₀ of 21–23 nmol/L. Functionally, Foretinib blocks HGF-induced cell motility, induces G2/M phase cell cycle arrest, and reduces proliferation. In vivo, Foretinib reduces tumor nodule formation and weight in ovarian cancer xenograft models when administered orally at 30 mg/kg. The compound’s broad target spectrum enables simultaneous disruption of angiogenic and growth-promoting signaling, which is critical for advanced cancer models (Schwartz 2022).

Evidence & Benchmarks

• Foretinib inhibits VEGFR2, VEGFR3, Met, KIT, Flt-3, PDGFRα/β, Tie-2, and Ron with IC₅₀ values from 0.4 to 9.6 nmol/L under in vitro kinase conditions (APExBIO).
• Cellular MET inhibition is achieved at IC₅₀ ≈ 21–23 nmol/L in B16F10, PC-3, A549, and HT29 cells (DMSO vehicle, 24 h, 37°C) (Schwartz 2022).
• Foretinib blocks HGF-induced cell motility and induces G2/M phase arrest in tumor cell lines in a concentration-dependent manner (Schwartz 2022).
• In vivo, oral Foretinib at 30 mg/kg reduces metastatic tumor nodules and tumor weight in ovarian cancer xenograft mouse models (NOD/SCID, female, 6–8 weeks, daily x 21 days) (APExBIO).
• Foretinib is soluble at ≥31.65 mg/mL in DMSO but insoluble in water and ethanol; stock solutions should be stored at -20°C and used promptly for experimental fidelity (APExBIO).

Applications, Limits & Misconceptions

Key Applications

• In vitro cell viability and cell motility inhibition assays for dissecting VEGFR and HGF/Met signaling (Schwartz 2022).
• Preclinical in vivo cancer metastasis models, including ovarian and melanoma xenografts.
• Mechanistic studies of multikinase inhibition and resistance pathways.
• Use as a tool in workflow integration for quantitative drug response studies (see related article; this article extends protocol detail and storage guidance beyond standard summaries).

Common Pitfalls or Misconceptions

• Not water-soluble: Foretinib is insoluble in water or ethanol, and improper solvent use can lead to precipitation and data artifacts (APExBIO).
• Not selective for a single kinase: Foretinib is a multikinase inhibitor; interpretation of results must consider off-target effects (Schwartz 2022).
• Not a diagnostic or therapeutic agent: Foretinib is for research use only and is not approved for clinical or diagnostic applications (APExBIO).
• Degradation risk: Stock solutions degrade if not stored at -20°C or if repeatedly thawed; always prepare fresh aliquots for critical assays.
• Cell-type variability: Responses may differ by cell line or assay system; cross-validation is recommended.

Workflow Integration & Parameters

For reproducible results, dissolve Foretinib in DMSO at ≥31.65 mg/mL. Prepare working dilutions freshly before use. Store stock aliquots at -20°C to prevent degradation. Avoid repeated freeze-thaw cycles. For in vitro cell-based assays, typical working concentrations range from 10–100 nM, with DMSO vehicle control at ≤0.1%. For in vivo studies, oral administration at 30 mg/kg daily is standard for xenograft models (e.g., NOD/SCID mice, 21-day protocol). Monitor vehicle and formulation compatibility to prevent precipitation. Integrate Foretinib into quantitative drug response workflows as outlined in recent advanced guides (related article; this review offers updated solubility and storage parameters not detailed previously). For advanced applications, combine with orthogonal readouts (e.g., cell cycle, motility, viability) in line with best practices for multikinase inhibitor profiling (related article; here, we clarify dosing and storage nuances for experimental rigor).

Conclusion & Outlook

Foretinib (GSK1363089) is a rigorously benchmarked ATP-competitive multikinase inhibitor for preclinical cancer research. Its validated nanomolar efficacy against VEGFR, HGFR/Met, and related kinases, combined with robust in vivo and in vitro performance, positions it as a standard tool for dissecting tumor biology and therapeutic resistance. Proper solvent selection, storage, and concentration control are critical for data fidelity. By integrating Foretinib into quantitative and mechanistic workflows, researchers can advance the precision and reproducibility of cancer signaling studies. For detailed product specifications and ordering, visit APExBIO’s Foretinib (GSK1363089) page.